Health Research

Leukemia: A Phase I/II Study of Decitabine in Combination with Sequential Rapamycin or Ribavirin in High Risk AML Patients

Basic Study Information

Will adding decitabine to sequntial rapamycin or ribavirin be beneficial in high risk AML patients?
The purpose of this study is to evaluate the response to chemotherapy with the drug decitabine combined with rapamycin in the treatment of relapsed or refractory acute myeloid leukemia in patients of all ages and in the treatment of newly diagnosed leukemia in those who are older than 65 when diagnosed. The safety of this combination has been previously studied but it is considered investigational for the treatment of refractory or relapsed leukemia. The study will determine whether this combination is not only safe but has benefit in reducing the amount of leukemia present in these patients.
Cancer center

Lead Researcher (Principal Investigator)

Jane Liesveld, MD

Study Contact Information

Katherine Nedrow
(585) 275-9485

Learn More About These Conditions